SEC Company Response from Avalo Therapeutics, Inc. (AVTX) (CIK 0001534120) (AVTX) — Dec 30, 2019
Avalo Therapeutics, Inc. (AVTX) (CIK 0001534120)
Date: Dec. 30, 2019 · CIK: 0001534120 · Accession: 0001104659-19-076569
AI Filing Summary & Sentiment
File numbers found in text: 333-235666
Show Raw Text
CORRESP 1 filename1.htm 540 Gaither Road, Suite 400 Rockville, MD 20850 December 30, 2019 VIA EDGAR Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Attn: Ada D. Sarmento Re: Cerecor Inc. Registration Statement on Form S-4 File No. 333-235666 Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, Cerecor Inc., a Delaware corporation (the “Registrant”), hereby requests that the Securities and Exchange Commission take appropriate action to make the Registration Statement on Form S-4 (File No. 333-235666) effective as of 4:05 p.m. Eastern Time, Tuesday, December 31, 2019, or as soon thereafter as practicable. The Registrant respectfully requests that its legal counsel be notified when this request for acceleration has been granted by contacting via telephone call or email, Andrew J. Gibbons (Tel: 919-786-4038; E-mail: agibbons@wyrick.com) The Registrant understands that the Commission will consider this request for acceleration of the effective date of the Registration Statement as a confirmation of the fact that the Registrant is aware of its responsibilities under the Securities Act and the Securities Exchange Act of 1934, as amended, as they relate to the proposed public offering of the securities specified in the Registration Statement. Very truly yours, CERECOR INC. By: /s/ Joseph M. Miller Name: Joseph M. Miller Title: Chief Financial Officer